REBECCA OLANDER: Open Payments
NPI 1174762405 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,587 in 89 payments from 17 companies in 2025. Trend: 2023 $1,579 · 2024 $1,308 · 2025 $1,587
Food & beverage: $1,587
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $449 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $197 |
| Otsuka America Pharmaceutical, Inc. | 14 | $165 |
| Supernus Pharmaceuticals, Inc. | 6 | $123 |
| Tris Pharma Inc | 5 | $112 |
| Alkermes, Inc. | 6 | $108 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| IDORSIA PHARMACEUTICALS US INC | 3 | $47 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Qelbree, Dyanavel XR, ARISTADA, Auvelity, Jornay PM.
Industry payments across NE — which companies pay providers there.
